Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus that emerged in 2019 and causes coronavirus disease 2019 (COVID-19). 1,2 SARS-CoV-2 is highly contagious. It differs from other respiratory viruses in that it appears that human-tohuman transmission occurs approximately 2 to 10 days prior to the individual becoming symptomatic. [2] [3] [4] The virus is transmitted from person to person through respiratory secretions. Large droplets from coughing, sneezing or rhinorrhoea land on surfaces within 2 m of the infected person. SARS-CoV-2 remains viable for at least 24 hours on hard surfaces and up to 8 hours on soft surfaces. 5 The virus is transferred to another person through hand contact on a contaminated surface followed by touching the mouth, nose or eyes. Aerosol airborne infected particles created during a sneeze or cough remain viable in the air for 3 hours. 5 These airborne particles of SARS-CoV-2 can then be inhaled by another person or land on the mucosal membranes of the eyes.
Individuals with COVID-19 can present with an influenza-like illness and respiratory tract infection demonstrating fever (89%), cough (68%), fatigue (38%), sputum production (34%) and/or shortness of breath (19%). 4 The spectrum of disease severity ranges from asymptomatic infection or mild upper respiratory tract illness through to severe viral pneumonia with respiratory failure and/or death. Current reports estimate that 80% of cases are asymptomatic or mild; 15% of cases are severe (infection requiring oxygen); and 5% are critical requiring ventilation and life support. 2 Preliminary reports indicate that chest radiographs may have diagnostic limitations in COVID-19. 6 Clinicians need to be aware that lung computed tomography (CT) scan findings often include multiple mottling and ground-glass opacity. 7 Lung ultrasound is also being used at the bedside with findings of multi-lobar distribution of Blines and diffuse lung consolidation. 8 The current mortality rate is 3 to 5%, with new reports of up to 9%, which is in contrast to influenza at around 0.1%. 2 The rates of admission to an intensive care unit (ICU) are approximately 5%. 4 Around 42% of patients admitted to hospital will require oxygen therapy. 4 Based on emerging data, individuals at highest risk of developing severe COVID-19 disease requiring hospitalisation and/or ICU support are those who are older, male, have at least one co-existing comorbidity, higher severity of illness scores (measured via SOFA scores), elevated D-dimer levels and/or lymphocytopenia. 2, 4, [9] [10] [11] Purpose This document has been prepared to provide information to physiotherapists and acute care healthcare facilities about the potential role of physiotherapy in the management of hospital-admitted patients with confirmed or suspected COVID- 19. Physiotherapists who work in primary healthcare facilities are likely to have a role in the management of patients admitted to hospital with confirmed or suspected COVID-19. Physiotherapy is an established profession throughout the world. Globally, physiotherapists often work in acute hospital wards and ICUs. In particular, cardiorespiratory physiotherapy focuses on the management of acute and chronic respiratory conditions and aims to improve physical recovery following an acute illness. Physiotherapy may be beneficial in the respiratory treatment and physical rehabilitation of patients with COVID-19. Although a productive cough is a less common symptom (34%), 4 physiotherapy may be indicated if patients with COVID-19 present with copious airway secretions that they are unable to clear independently. This may be evaluated on a case-bycase basis and interventions applied based on clinical indicators. High-risk patients may also benefit, for example: patients with existing comorbidities that may be associated with hypersecretion or ineffective cough (eg, neuromuscular disease, respiratory disease and cystic fibrosis). Physiotherapists who practise in the ICU environment may also provide airway clearance techniques for ventilated patients Box 1. Physiotherapy workforce planning and preparation recommendations. It is recommended that staff who are pregnant avoid exposure to COVID-19. It is known that pregnant women are potentially at increased risk of complications from any respiratory disease due to the physiological changes that occur in pregnancy. There is not enough currently available information on the impact of COVID-19 on a pregnant woman or her baby.
Workforce planning should include consideration for pandemic-specific requirements such as additional workload from donning and doffing PPE, and the need to allocate staff to key non-clinical duties such as enforcing infection control procedures. 12 1.10 Consider organising the workforce into teams that will manage COVID-19 versus non-infectious patients. Minimise or prevent movement of staff between teams. Liaise with local infection control services for recommendations.
Be aware of and comply with relevant international, national, state and/or hospital guidelines for infection control in healthcare facilities. For example, World Health Organization 'Guidelines for infection prevention and control during health care when novel coronavirus infection is suspected'. 19 1.12 Senior physiotherapists should be involved in determining the appropriateness of physiotherapy interventions for patients with confirmed or suspected COVID-19 in consultation with senior medical staff and according to a referral guideline.
Identify hospital-wide plans for allocation/cohorting patients with COVID-19. Utilise these plans to prepare resource plans that may be required. For example, Table 2 below is an example of a resource plan for ICU physiotherapy.
1.14 Identify additional physical resources that may be required for physiotherapy interventions and how the risk of cross-infection can be minimised (eg, respiratory equipment; mobilisation, exercise and rehabilitation equipment; and equipment storage).
Identify and develop a facility inventory of respiratory, mobilisation, exercise and rehabilitation equipment and determine the process of equipment allocation as pandemic levels increase (ie, to prevent movement of equipment between infectious and non-infectious areas).
It should be recognised that staff will likely have an increased workload with a heightened risk of anxiety both at work and home. 12 Staff should be supported during and beyond the active treatment phases (eg, via access to employee assistance programs, counselling and facilitated debriefing sessions).
Consider and/or promote debriefing and psychological support; staff morale may be adversely affected due to the increased workload, anxiety over personal safety and the health of family members. 12 COVID-19 = coronavirus disease 2019, ICU = intensive care unit, PPE = personal protective equipment.
who show signs of inadequate airway clearance and they can assist in positioning patients with severe respiratory failure associated with COVID-19, including the use of prone position to optimise oxygenation. 12 Given the intensive medical management for some COVID-19 patientsincluding prolonged protective lung ventilation, sedation and use of neuromuscular blocking agentsthose who are admitted to ICU may be at high risk of developing ICU-acquired weakness; 13 The respiratory infection associated with COVID-19 is mostly associated with a dry and non-productive cough; lower respiratory tract involvement usually involves pneumonitis rather than exudative consolidation. 20 In these cases, respiratory physiotherapy interventions are not indicated.
Respiratory physiotherapy interventions in hospital wards or ICU may be indicated for patients who have confirmed or suspected COVID-19 and concurrently or subsequently develop exudative consolidation, mucous hypersecretion and/or difficulty clearing secretions.
Physiotherapists will have an ongoing role in providing interventions for mobilisation, exercise and rehabilitation (eg, in patients with comorbidities creating significant functional decline and/or (at risk of) ICU-acquired weakness).
Physiotherapy interventions should only be provided when there are clinical indicators, so that staff exposure to patients with COVID-19 is minimised. Unnecessary review of patients with COVID-19 within their isolation room/areas will also have a negative impact on PPE supplies.
Physiotherapists should meet regularly with senior medical staff to determine indications for physiotherapy review in patients with confirmed or suspected COVID-19 and screen according to set/agreed guidelines (Table 1 provides a suggested framework).
Physiotherapy staff should not be routinely entering isolation rooms, where patients with confirmed or suspected COVID-19 are isolated or cohorted, just to screen for referrals.
Options for screening patients via subjective review and basic assessment whilst not being in direct contact with the patient should be trialled first whenever possible (eg, calling the patient's isolation room telephone and conducting a subjective assessment for mobility information and/or providing education on airway clearance techniques).
COVID-19 = coronavirus disease 2019, ICU = intensive care unit, PPE = personal protective equipment. this may worsen their morbidity and mortality. 14 It is therefore essential to initiate early rehabilitation after the acute phase of respiratory distress in order to limit the severity of ICU-acquired weakness and promote rapid functional recovery. Physiotherapy will have a role in providing exercise, mobilisation and rehabilitation interventions to survivors of critical illness associated with COVID-19 in order to enable a functional return to home.
This document focuses on the adult acute hospital setting. The recommendations for physiotherapists are outlined below in two sections: workforce planning and preparation, including screening to determine indications for physiotherapy; and delivery of physiotherapy interventions, including both respiratory and mobilisation/rehabilitation as well as personal protective equipment (PPE) requirements.
It is recognised that physiotherapy practices vary across the world. When using these recommendations, the scope of practice within the local context should be considered. a
A group of international experts in cardiorespiratory physiotherapy came together to rapidly prepare clinical recommendations for physiotherapy management of COVID-19. The author group initially convened on 20 March 2020 to discuss the urgent need for worldwide acute care physiotherapy guidance in relation to COVID-19. Efforts were quickly prioritised to develop specific guidance for physiotherapists in the acute care settings.
The AGREE II framework 15 was used to guide development, and recognising the expediency of this work required pragmatic and transparent reporting. Conduct was modelled after the GRADE Adolopment Process 16 and Evidence to Decision framework 17 Through a web search and personal files, recently developed guidelines for COVID-19 management of critically ill patients were identified from international agencies (eg, World Health Organization), critical care professional societies or groups (eg, Australia and New Zealand Intensive Care Society, Society of Critical Care Medicine/ European Society of Intensive Care Medicine), or physiotherapy professional societies up to 21 March 2020. These guidelines were used to inform the consensus recommendations developed in conjunction with expert opinion of the authorship group.
A priori it was decided to develop consensus recommendations, given the time-sensitive nature of the guidance. It was agreed that a 70% agreement was required for a recommendation. On Friday 20 March 2020 the lead author (PT) circulated draft recommendations to all authors. All authors independently returned comments to the lead author. The lead author (PT) collated all comments for further discussion. All recommendations were discussed in a teleconference on 22 March 2020. Fourteen people participated in the development process and 66 recommendations were developed. A consensus of . 70% was achieved for all items. Further discussion was focused on greater clarity in wording and/or reduction of items where overlap occurred.
Endorsement for the recommendations was sought from physiotherapy societies, physiotherapy professional groups and the World Confederation for Physical Therapy. The recommendations were circulated to these groups on 23 March 2020, requesting endorsement; endorsements will be updated as they are confirmed.
This document has several strengths. It responds to an urgent need for clinical guidance for acute care physiotherapists worldwide. Table 3 Specific respiratory interventions.
The following procedures create an airborne risk of transmission of COVID-19: intubation/extubation bronchoscopy high-flow nasal oxygen use non-invasive ventilation tracheostomy cardiopulmonary resuscitation prior to intubation 12, 22 Additional aerosol-generating procedures related to physiotherapy techniques are outlined in Box 3.
High-flow nasal oxygen This is a recommended therapy for hypoxia associated with COVID-19, as long as staff are wearing optimal airborne PPE. 12 At flow rates 40 to 60 l/min, high-flow nasal oxygen does carry a small risk of aerosol generation. The risk of airborne transmission to staff is low when optimal PPE and other infection control precautions are being used. 23 Negative pressure rooms are preferable for patients receiving high-flow nasal oxygen. 12 Respiratory support via high-flow nasal oxygen should be restricted to patients in airborne isolation rooms only. Limiting the flow rate to no more than 30 l/min might reduce potential viral transmission.
Non-invasive ventilation Routine use is not recommended 12 because current experience with COVID-19 hypoxic respiratory failure has a high associated failure rate. If used (eg, with a patient with chronic obstructive pulmonary disease or post-extubation), it must be provided with strict airborne PPE. 12 Oxygen therapy Treatment targets may vary depending on the presentation of the patient. For patients presenting with severe respiratory distress, hypoxaemia or shock, SpO 2 . 94% is targeted. 23 Once a patient is stable, the SpO 2 target is . 90% in non-pregnant adults 24 and 92 to 95% in pregnant patients. 23 In adults with COVID-19 and acute hypoxaemic respiratory failure, the SpO 2 target should not be maintained . 96%. 22
The use of nebulised agents (eg, salbutamol, saline) for the treatment of non-intubated patients with COVID-19 is not recommended because it increases the risk of aerosolisation and transmission of infection to healthcare workers in the immediate vicinity.
Use of metered-dose inhalers or spacers is preferred where possible. 12 If a nebuliser is required, liaise with local guidelines for directions to minimise aerosolisation (eg, use of a Pari Sprint with inline viral filter).
Use of nebulisers, non-invasive ventilation, high-flow nasal oxygen and spirometry should be avoided and agreement to their use sought from senior medical staff. 20 If deemed essential, airborne precautions should be used. Guidance was based on the most recent and relevant COVID-19 clinical practice guidelines from highly-respected organisations, national physiotherapy organisations and peer-reviewed studies; these sources were transparently reported. The authors represent an international group of physiotherapists, with extensive clinical experience in the ICU and on the wards. They are also academic physiotherapists with experience in the leadership, conduct and execution of rigorous systematic reviews, clinical studies (including prospective cohort studies and international multi-centre trials), and clinical practice guidelines. The recommendations have been endorsed by international physiotherapy organisations. b Translations of the recommendations are available in Appendix 1 on the eAddenda. There are also some limitations. Given the recent presentation of COVID-19, clinical guidance may change as more is learnt about the natural history of this disease. Recommendations were extrapolated based on best evidence for current management of critically ill patients and long-term outcomes in critical illness survivors. No patient was included in the author group. While the recommendations apply to physiotherapy interventions in the acute-care setting, longer-term follow-up of survivors is needed.
COVID-19 is placing significant demands on healthcare resources throughout the world. Box 1 outlines recommendations to assist the physiotherapy workforce to plan and respond to this demand. Box 2 and Table 1 provide recommendations for determining whom physiotherapists should treat when patients have confirmed or suspected COVID-19. Table 2 provides an example of a resource plan for ICU physiotherapy from Tier 0 (business as usual) through to Tier 4 (largescale emergency). Local context, resources and expertise should be considered when utilising this example resource plan.
It is important for physiotherapists to be aware of the medical management for patients with COVID-19. Table 3 summarises some of the recommendations available from medical guidelines developed by professional societies (as listed in Appendix 2 on the eAddenda).
For patients admitted to ICU, additional strategies may be used; these are summarised in Table 4 . With increasing acuity, there is an increased risk of dispersion of aerosolised virus into the healthcare environment due to the nature of critical illness, higher viral load and the performance of aerosol-generating procedures. It is recommended that airborne PPE precautions should be used to care for all patients with COVID-19 in ICU. 12 Recommendations for the delivery of physiotherapy interventions, including personal protective equipment requirements
Examples of physiotherapy-led respiratory interventions (or chest physiotherapy) are provided below.
Airway clearance techniques include positioning, active cycle of breathing, manual and/or ventilator hyperinflation, percussion and vibrations, positive expiratory pressure therapy (PEP) and mechanical insufflation-exsufflation.
Physiotherapists may use inspiratory positive pressure breathing (eg, for patients with rib fractures). Non-invasive ventilation may be applied as part of airway clearance strategies in the management of respiratory failure or during exercise.
Techniques to facilitate secretion clearance include assisted or stimulated cough manoeuvres and airway suctioning.
Physiotherapists prescribe exercise and assist patients to mobilise. Physiotherapists also play an integral role in the management of patients with a tracheostomy.
COVID-19 poses significant considerations for respiratory physiotherapy interventions due to their aerosol-generating procedures. Box 3 outlines recommendations for providing respiratory care to patients with COVID-19. Table 4 Additional respiratory interventions in the ICU.
Patients with worsening hypoxia, hypercapnia, acidaemia, respiratory fatigue, haemodynamic instability or those with altered mental status should be considered for early invasive mechanical ventilation if appropriate. 12 The risk of aerosol transmission is reduced once a patient is intubated with a closed ventilator circuit. 12 Recruitment manoeuvres Although current evidence does not support the routine use of recruitment manoeuvres in non-COVID-19 ARDS, they could be considered in patients with COVID-19 on a case-by-case basis. 12 Prone positioning Anecdotal reports from international centres dealing with large numbers of critically ill patients with COVID-19-related ARDS suggest that prone ventilation is an effective strategy in mechanically ventilated patients. 12 In adult patients with COVID-19 and severe ARDS, prone ventilation for 12 to 16 hours per day is recommended. 22, 23 It requires sufficient human resources and expertise to be safely performed, to prevent known complications including pressure areas and airway complications.
Bronchoscopy carries a significant risk of aerosol generation and transmission of infection. The clinical yield is thought to be low in COVID-19 and unless there are other indications (such as suspected atypical/opportunistic superinfection or immunosuppression) it is strongly advised to avoid the procedure. 12 Suctioning Closed inline suction catheters are recommended. 12 Sputum samples In a ventilated patient, tracheal aspirate samples for diagnosis of COVID-19 are sufficient and bronchoalveolar lavage is not usually necessary. 12 Any disconnection of the patient from the ventilator should be avoided to prevent lung decruitment and aerosolisation. If necessary, the endotracheal tube should be clamped and the ventilator disabled (to prevent aerosolisation). 12 Tracheostomy Tracheostomy could be considered in suitable patients to facilitate nursing care and expedite ventilator weaning, but is an aerosolising procedure and this must be considered in clinical decision making. 12 ARDS = acute respiratory distress syndrome, COVID-19 = coronavirus disease 2019, ICU = intensive care unit. 
Where aerosol-generating procedures are indicated and considered essential they should be undertaken in a negative-pressure room, if available, or in a single room with the door closed. Only the minimum number of required staff should be present and they must all wear PPE, as described. Entry and exit from the room should be minimised during the procedure. 12 This may not be able to be maintained when cohorting is required because of the volume of patients presenting with COVID-19.
BubblePEP is not recommended for patients with COVID-19 because of uncertainty around the potential for aerosolisation, which is similar to the caution the WHO places on bubble CPAP. 23 
There is no evidence for incentive spirometry in patients with COVID-19.
Avoid the use of mechanical insufflation/exsufflation, non-invasive ventilation, inspiratory positive pressure breathing devices or high-flow nasal oxygen devices. However, if clinically indicated and alternative options have been ineffective, consult with both senior medical staff and infection prevention and monitoring services within local facilities prior to use.
If used, ensure that machines can be decontaminated after use and protect machine with viral filters over machine and patient ends of circuits: Use disposable circuits for these devices. Maintain a log of devices that includes patient details for tracking and infection monitoring (if required). Use airborne precautions.
Where respiratory equipment is used, whenever possible, use single-patient-use disposable options (eg, single-patient-use PEP devices).
Re-usable respiratory equipment should be avoided where possible.
Physiotherapists should not implement humidification, non-invasive ventilation or other aerosol-generating procedures without consultation and agreement with a senior doctor (eg, medical consultant).
3.10 Sputum inductions should not be performed.
Requests for sputum samples
In the first instance, ascertain whether the patient is productive of sputum and able to clear sputum independently. If so, physiotherapy is not required for a sputum sample.
If physiotherapy interventions are required to facilitate a sputum sample, full airborne PPE should be worn. The handling of sputum samples should adhere to local policies. Generally, once a sputum sample has been obtained the following points should be followed: All sputum specimens and request forms should be marked with a biohazard label. The specimen should be double-bagged. The specimen should be placed in the first bag in the isolation room by a staff member wearing recommended PPE. Specimens should be hand-delivered to the laboratory by someone who understands the nature of the specimens. Pneumatic tube systems must not be used to transport specimens.
3.12 Do not use saline nebulisation. It should be noted that some UK guidelines allow use of nebulisers, but this is currently not recommended in Australia.
As it involves disconnection/opening of a ventilator circuit, avoid manual hyperinflation and utilise ventilator hyperinflation if indicated (eg, for suppurative presentations in ICU and if local procedures are in place).
(Continued on next page) 
Personal protective equipment 4.1 Droplet precautions should be appropriate for the provision of mobilisation, exercise and rehabilitation in most circumstances. However, physiotherapists are likely to be in close contact with the patient (eg, for mobilisation, exercise or rehabilitation interventions that require assistance). In these cases, consider use of a high filtration mask (eg, P2/N95). Mobilisation and exercise may also result in the patient coughing or expectorating mucus, and there may be circuit disconnections with ventilated patients. Refer to local guidelines regarding ability to mobilise patients outside of their isolation room. If mobilising outside of the isolation room, ensure that the patient is wearing a surgical mask.
Physiotherapists will actively screen and/or accept referrals for mobilisation, exercise and rehabilitation. When screening, discussion with nursing staff, the patient (eg, via phone) or family is recommended before deciding to enter the patient's isolation room. For example, to try to minimise staff who come in to contact with patients with COVID-19, physiotherapists may screen to determine an appropriate aid to trial. A trial of the aid may then be performed by the nursing staff already in an isolation room, with guidance provided, if needed, by the physiotherapist who is outside the room.
Direct physiotherapy interventions should only be considered when there are significant functional limitations, such as (risk of) ICU-acquired weakness, frailty, multiple comorbidities and advanced age.
Early mobilisation
Early mobilisation is encouraged. Actively mobilise the patient early in the course of illness when safe to do so. 23 4.5 Patients should be encouraged to maintain function as able within their rooms: Sit out of bed. Perform simple exercises and activities of daily living.
Mobilisation and exercise prescription 4.6 Mobilisation and exercise prescription should involve careful consideration of the patient's state (eg, stable clinical presentation with stable respiratory and haemodynamic function). 26, 27 Mobility and exercise equipment 4.7
The use of equipment should be carefully considered and discussed with local infection monitoring and prevention service staff before being used with patients with COVID-19 to ensure that it can be properly decontaminated.
Use equipment that can be single patient use. For example, use elastic resistance bands rather than distributing hand weights.
Larger equipment (eg, mobility aids, ergometers, chairs and tilt tables) must be easily decontaminated. Avoid use of specialised equipment, unless necessary, for basic functional tasks. For example, stretcher chairs or tilt tables may be deemed appropriate if they can be decontaminated with appropriate cleaning and are indicated for progression of sitting/standing.
When mobilisation, exercise or rehabilitation interventions are indicated: Plan well. Identify/use the minimum number of staff required to safely perform the activity. 26 Ensure that all equipment is available and working before entering rooms. Ensure that all equipment is appropriately cleaned or decontaminated.
If equipment needs to be shared among patients, clean and disinfect between each patient use. 23 Specific staff training for cleaning of equipment within isolation rooms may be required. Whenever possible, prevent the movement of equipment between infectious and non-infectious areas. Whenever possible, keep dedicated equipment within the isolation zones, but avoid storing extraneous equipment within the patient's room.
When performing activities with ventilated patients or patients with a tracheostomy, ensure that airway security is considered and maintained (eg, a dedicated airway person to prevent inadvertent disconnection of ventilator connections/tubing).
COVID-19 = coronavirus disease 2019, ICU = intensive care unit.
Physiotherapists are responsible for providing musculoskeletal, neurological and cardiopulmonary rehabilitation tasks, as outlined below.
Passive, active-assisted, active or resisted joint range of motion exercises may be performed to maintain or improve joint integrity, range of motion and muscle strength.
Examples of mobilisation and rehabilitation include bed mobility, sitting out of bed, sitting balance, sit to stand, walking, tilt table, standing hoists, upper/lower limb ergometry and exercise programs.
Box 4 outlines recommendations for implementing these activities in patients with COVID-19.
It is imperative that physiotherapists understand the measures in place to prevent transmission of COVID-19. Box 5 provides recommendations for this. Patients with confirmed or suspected COVID-19 will be managed with either droplet or airborne precautions. 12 Additionally, they will be placed in isolation. Hospitals are often able to contain patients with droplet or airborne spread within dedicated isolation rooms. However, there are a limited number of negative pressure bays and pods and/or rooms across Australia and New Zealand, 12 so isolation within dedicated rooms may not be possible with COVID-19 because of the large volume of patient admissions.
It is important for physiotherapists to understand the different types of isolation rooms that exist in hospitals. Class S rooms (standard single rooms, no negative pressure capability), which can be used for isolating patients capable of transmitting infection by droplet or contact routes 12 and Class N rooms (single negative pressure isolation rooms), which are beneficial in isolating patients with transmissible airborne infections. 12 The preference would be for patients with confirmed or suspected COVID-19 to be isolated in Class N rooms. 12 If this is not possible, Class S single rooms with clearly designated areas for donning and doffing PPE are recommended. 12 In the event of all single Class N and S rooms being fully occupied, the recommendation is for patients with COVID-19 to be separately Box 5. Recommendations regarding personal protective equipment for physiotherapists.
All staff must be trained in correct donning and doffing of PPE, including N95 'fit-checking'. A registry of staff who have completed PPE education and fit checking should be maintained.
'Fit testing' is recommended when available, but the evidence for fit testing effectiveness is limited and the variation in supply of N95 mask types may make any recommendation on fit testing difficult to implement from a practical perspective. 12 
Staff with beards should be encouraged to remove facial hair to ensure good mask fit. 24 
For all confirmed or suspected cases, droplet precautions should be implemented, at a minimum. Staff must wear the following items: surgical mask fluid-resistant long-sleeved gown goggles or face shield gloves 22 
Recommended PPE for staff caring for COVID-19-infected patients includes added precautions for patients with significant respiratory illness, when aerosolgenerating procedures are likely and/or prolonged or very close contact with the patient is likely. In these cases, airborne precautions are followed, including: an N95/P2 mask fluid-resistant long-sleeved gown goggles or face shield gloves 24
In addition, the following can be considered: hair cover for aerosol-generating procedures shoes that are impermeable to liquids and can be wiped down Recurrent use of shoe covers is not recommended, as repeated removal is likely to increase the risk of staff contamination. 12 5.7 PPE must remain in place and be worn correctly for the duration of exposure to potentially contaminated areas. PPE (particularly masks) should not be adjusted during patient care. 24 5.8 Use a step-by-step process for donning and doffing PPE as per local guidelines. 24 
Check local guidelines for information on laundering uniforms and/or wearing uniforms outside of work if exposed to COVID-19. For example, changing into scrubs may be recommended in local guidelines 12 and/or staff may be encouraged to get changed out of their uniform before leaving work and to transport worn uniforms home in a plastic bag for washing at home.
Minimise personal effects in the workplace. All personal items should be removed before entering clinical areas and donning PPE. This includes earrings, watches, lanyards, mobile phones, pagers, pens, etc.
Stethoscope use should be minimised. 12 If required, use dedicated stethoscopes within isolation areas. 19, 23 Hair should be tied back out of the face and eyes. 24 
Staff caring for infectious patients must apply correct PPE, irrespective of physical isolation. 
When a unit is caring for a patient with confirmed or suspected COVID-19, it is recommended that all donning and doffing are supervised by an additional appropriately trained staff member. 12 
Avoid sharing equipment. Preferably only use single-use equipment.
Wear an additional plastic apron if a large volume of fluid exposure is expected. 24 
If reusable PPE items are used (eg, goggles), these must be cleaned and disinfected prior to re-use. 24 COVID-19 = coronavirus disease 2019, ICU = intensive care unit, PPE = personal protective equipment.
cohorted to patients without COVID-19 within the hospital. 12 In an open ICU or ward-cohorted areas with one or more patients with COVID-19, it is recommended that staff members in the whole area are required to use airborne PPE precautions. 12 Box 5 describes how the movement from dedicated isolation rooms to open cohorting might evolve within an ICU. Footnotes: a An international team of expert researchers and clinicians within the intensive care and acute cardiorespiratory fields have developed these recommendations. The recommendations are intended for use in adults only. This document has been constructed using existing medical guidelines, relevant literature and expert opinion. The authors have made considerable effort to ensure that the information contained with the recommendation is accurate at time of publication. Further iterations of these recommendations will be published as new information arises. The information provided in this document is not designed to replace local institutional policies and should not replace clinical reasoning for individual patient management. The authors are not liable for the accuracy, information that may be perceived as misleading, or completeness of information in this document. The author group will review and update this guidance within 6 months, or if important new evidence emerges that changes the recommendations herein. b These recommendations have been endorsed by: Australian Physiotherapy Association, Canadian Physiotherapy Association, Association of Chartered Society of Physiotherapists in Respiratory Care UK, Associazione Riabilitatori dell' Insufficienza Respiratoria, Koninklijk Nederlands Genootschap voor Fysiotherapie, International Confederation of Cardiorespiratory Physical Therapists, World Confederation for Physical Therapy, AXXON Physical Therapy in Belgium, and Société de Kinésithérapie de Réanimation. eAddenda: Appendices 1 and 2 can be found online at https:// doi.org/10.1016/j.jphys.2020.03.011.
Ethics approval: Not applicable.
Competing interest: All authors completed a World Health Organization conflict of interest form. Direct financial and industryrelated conflicts of interest were not permitted and were considered to be disqualifying. The development of these recommendations did not include any industry input, funding, or financial or non-financial contribution. No author received honoraria or remuneration for any role in the development process. We explicitly discussed conflicts of interest, including those who held grants related to intensive care unit rehabilitation (CH, MK, SMP) or received industry funding for high-flow nasal cannula research (IB); because none of these projects specifically involved COVID-19, the group agreed that there were no relevant conflicts of interest.
Sources of support: Nil.